Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Antiviral Drugs market.
Trusted Business Insights presents an updated and Latest Study on Antiviral Drugs Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Antiviral Drugs market during the forecast period (2019-2029).
It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.
Get Sample Copy of this Report @ Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)
The global antiviral drugs market size was USD 36.1 billion in 2018 and is projected to reach USD 44.2 billion by 2026, exhibiting a CAGR of 3.2% during the forecast period.
We have updated Antiviral Drugs Market with respect to COVID-19 Impact.
Inquire before buying
Virus is a particle of RNA or DNA enclosed in a structural protein. They infect the human cells and proliferate to cause viral infections. Viral infection is considered to be one of the most common causes of human illness and has a significant impact on the healthcare system across the globe. The infections spread rapidly in the community and are responsible for considerable morbidity. They can be severe and require a systematic approach for their management. In the developed economies, it is estimated that around 30% to 40% of the infectious gastroenteritis cases are attributable to viruses. Antiviral agents are thus, the therapeutics that restore the normal function of cells and eliminate the viral infection. They generally inhibit the replication of viruses inside the body.
Various pharmaceutical companies are engaged in developing novel antiviral therapies across the globe to prevent the spread of communicable viral infections. Rising burden of viral diseases, especially in the developing nations and improved research collaboration of industries in the development of blockbuster therapeutics are the key factors associated with the antiviral drugs market growth. For instance, around 125,000 to 200,000 infections occur annually in the U.S., out of which about 70% of adults are symptomatic, according to the Centers for Disease Control and Prevention. Such increasing prevalence of viral disease is expected to boost the antiviral drugs market size during the forecast period. There are over a thousand different types of viruses that infect humans and they account for around 60% of all human infections. However, lack of rapid diagnostic reagents and the speedy replication of viruses make it difficult to develop potent and effective antiviral therapy.
Rising Prevalence of HIV and Influenza to Fuel Growth of Market
HIV is emerging as the most common form of viral infection across the globe. Enhanced surveillance for HIV by using demographic and biological data has improved the diagnosis rate of the disease. According to WHO, around 37.9 million people were living with HIV in the globe in 2018, while 770,000 people died of this disease. Hence, the increasing burden of this infection is boosting the demand for targeted and specific treatment regimen and in-turn propeling the antiviral agents market growth.
Moreover, the rising incidence rate of influenza and its quick diagnosis are contributing to the high demand for antiviral therapeutics across the globe.
Introduction of Blockbuster Therapeutics to Boost the Market
Various key pharmaceutical giants are actively investing in the research and development of antiviral agents. The introduction of blockbuster drugs, such as Biktarvy by Gilead Science and Triumeq by GlaxoSmithKline have changed the face of antiretroviral therapy. Rising uptake of such blockbuster agents and their improved distribution by the manufacturers are likely to propel the antiviral market revenue during 2019-2026. Biktarvy received approval in February 2018 and it is targeting the populaces that are living with HIV globally. Out of those, around 21 million people are receiving antiretroviral therapy which allows the immune system to strengthen.
By Drug Class Analysis
Combination Drugs Segment to Witness Remarkable Growth
Based on the drug class, the antiviral medication market is classified as protease inhibitors, polymerase inhibitors, integrase inhibitors, combination drugs, reverse transcriptase inhibitors, and others. Out of these, the combination drugs segment accounted for the highest market share in 2018, which is attributable to the remarkable performance of combination brands, such as Genvoya, Mavyret, Triumeq, etc. Also, green signal by USFDA for the launch of novel combination therapies of antiviral medication for flu is anticipated to boost the growth of this segment during 2019-2026.
The integrase inhibitors segment is projected to expand in the coming years owing to the remarkable performance of drugs, such as Tivicay and Isentress/Isentress HD. It is a well-tolerated class of antiretroviral drugs and has relatively higher potency than the other antiviral agents. These are the key factors for the significant investment in the R&D of integrase inhibitors and the estimated growth of this segment.
By Disease Indication Analysis
Human Immunodeficiency Virus (HIV) Segment to Dominate the Market
On the basis of disease indication, the antiviral therapeutics market is segmented into hepatitis, human immunodeficiency virus (HIV), influenza, and others. The others segment is further comprised of herpes infection, rotavirus infection, etc. The HIV segment registered the maximum market share in 2018, owing to the rapid rise in the prevalence of HIV infection. Also improved treatment regimen for HIV infection and favorable reimbursement policies for antiretroviral therapy in several countries are anticipated to augment the growth of this segment. It is, in turn, set to impact the market positively during the forthcoming period.
Participation of the governments in developing economies to promote virology education and to address the unmet need for effective antiviral therapeutics, especially for HIV infection, are improving the collaborative research for antiretroviral drugs. Moreover, the development of comprehensive guidelines on HIV-preventive interventions and evaluation of HIV preventive capacity of drug treatment services by WHO are likely to enhance the demand for HIV drugs during the forecast period.
By Distribution Channel Analysis
Strong Government Support to Favor the Hospital Pharmacy Segment
In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online channel. Strong government support for viral diseases through establishment of government-aided hospital pharmacies, favorable reimbursement policies, and improved supply network of key companies are the major factors attributable to the expansion of the hospital pharmacy segment. The online channel segment is expected to register a relatively significant CAGR during the forecast period, due to the emergence of online pharmacy offering discounts and their rapid adoption by the masses. The retail pharmacy segment is anticipated to expand on account of the increasing patient pool and availability of OTC and generic medications for minor viral infections.
North America, with a revenue of USD 13.9 billion in 2018, accounted for a major antiviral drugs market share. This is attributable to the strategic presence of key pharmaceutical giants in the U.S., increased prevalence of infections such as HIV in the country, and green signal by USFDA for the launch of blockbuster and effective therapies in North America. Europe is anticipated to witness a remarkable growth in the coming years owing to the favorable reimbursement policies for antiviral therapy and key players involved in the R&D of antiviral medication for HIV.
However, Asia Pacific is anticipated to reflect a relatively higher CAGR during the forecast period, which is attributable to the established supply network, improved pharmaceutical industry in countries, such as India and Japan, and frequent outburst of viral diseases, such as Ebola, dengue, and swine flu in the developing nations. Government participation in the management of viral infections in Brazil & Mexico and rising penetration of generic pharmaceutical companies are expected to boost the size of Latin America antiviral medication market during 2019-2026. Also, efforts made by public players to improve the awareness for key viral infections, such as HIV in the Middle East & Africa and effective therapeutics launches in countries such as South Africa are projected to augment the revenue generation from Middle East & Africa in the coming years.
In Europe, the market is estimated to flourish owing to new product launches, favorable health reimbursement, and active government support. In April 2019, Boehringer Ingelheim, a Germany based company, collaborated with PureTech Health, which will help the former to apply PureTech™s lymphatic targeting platform to the company™s immuno-oncology candidate for gastric cancer. As a result, the drug can be administrated directly to the gut lymphatics. The expected launch of such drugs that can be directly administered to the site is anticipated to fuel the market in Europe. In Latin America and the Middle East & Africa, the demand for gastric carcinoma treatment are projected to boost owing to the improving health infrastructure, unmet patient needs, and the launch of new products.
INDUSTRY KEY PLAYERS
Gilead Sciences and GlaxoSmithKline to Lead the Market
In terms of revenue, Gilead Sciences dominated the antiviral agents market owing to the remarkable sale of its drugs such as Biktarvy, Harvoni, etc. Genvoya, a leading fixed dose combination antiretroviral drug by Gilead, accounted for a revenue of more than USD 4.5 billion in 2018, which propelled the market share of the company. Another leading combination called Triumeq by GSK, generated over USD 3.4 billion revenue in 2018, which has provided a strategic position to the company in global market. Another key player operating in the market is Abvie. The company is growing because of its significant performance in Hepatitis C.
List of key Companies Covered:
- Gilead Sciences
- Abbvie, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Mylan N.V.
- Novartis AG
The antiviral therapy has evolved over the years and is expanding at a rapid rate with the introduction of effective therapeutics by key companies. Investment by key pharmaceutical manufacturers in the R&D aiming to eradicate the viruses that are resistant to the existing traditional antiviral therapy, is changing the scenario of antiviral therapeutics market. Moreover, strong pipeline of the companies is expected to boost the market growth in coming years. For instance, Gilead Sciences entered in an antiviral deal with Novartis to gain exclusive rights to preclinical programs involving candidates for the treatment of herpes viruses, human rhinovirus, and influenza.
The research report offers an in-depth analysis of the market. It further provides details on the prevalence of key viral infections for major countries, regulatory and reimbursement scenario for key countries, new product launches, and key industry developments, such as mergers, acquisitions, and partnerships. Information on drivers, opportunities, threats, and restraints of the market can further help stakeholders to gain valuable insights into the market. The report offers a detailed competitive landscape by presenting information on key players, along with their strategies, in the market.
Report Scope & Segmentation
By Drug Class
- Protease Inhibitors
- Polymerase Inhibitors
- Integrase Inhibitors
- Reverse Transcriptase Inhibitors
- Combination Drugs
By Disease Indication
- Human Immunodeficiency Virus (HIV)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Channel
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East and Africa (South Africa, GCC, and Rest of Middle East & Africa)
April 2019: Gilead Sciences, one of the major antiviral drugs manufacturers, submitted a supplemental New Drug Application (sNDA) to the USFDA for Descovy, for pre-exposure prophylaxis, to reduce the risk of sexually acquired HIV infection among individuals who are HIV-negative and at risk for HIV.
December 2019: GlaxoSmithKline submitted a new drug application to the USFDA seeking approval for fostemsavir, an experimental treatment for HIV in adults.
August 2017: Abbvie received a USFDA approval for MAVYRET, a ribavirin-free treatment option for adults with chronic hepatitis C virus (HCV) infection.
Quick Read Table of Contents of this Report @ Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)
Trusted Business Insights
Media & Marketing Executive
Email Me For Any Clarifications
Connect on LinkedIn
Click to follow Trusted Business Insights LinkedIn for Market Data and Updates.
US: +1 646 568 9797
UK: +44 330 808 0580